Assess whether pediatric studies are necessary or waivable (aac098)

Situation

A company with a CMC site change mid-review cannot treat a DSMB note on an imbalance that is not yet a signal as color commentary on 505(b)(2) literature-to-product bridge table. Labeling negotiator must close pediatric studies are necessary from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

Labeling negotiator in a company with a CMC site change mid-review must choose Pediatric studies are necessary / Waivable using 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• Labeling negotiator can defend Pediatric studies are necessary from 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge.
• Labeling negotiator cannot defend Pediatric studies are necessary from 505(b)(2) literature-to-product bridge table; Waivable is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal.
• A DSMB note on an imbalance that is not yet a signal never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close pediatric studies are necessary.
• Two facts in 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal conflict for labeling negotiator; hold this Pharmacovigilance file.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move pediatric studies are necessary for labeling negotiator.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for labeling negotiator in a company with a CMC site change mid-review.